Autoinjectors Market

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023

Report Code: MD 6494 Aug, 2018, by marketsandmarkets.com
COVID-19

Get in-depth analysis of the COVID-19 impact on the Autoinjectors Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Autoinjectors Market

Request For Special Pricing

[133 Pages Report] Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs.

The autoinjectors market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2%. Growth in the global autoinjectors market is mainly driven by factors such as the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements in autoinjector devices. The patent expiry of biologics in the coming years is also expected to provide growth opportunities for players in the autoinjectors market.

Autoinjectors Market

Disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period.

Disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need for manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.

The rheumatoid arthritis segment to account for the largest share of the autoinjectors market.

The demand for autoinjectors for this therapy segment is fueled by the increasing incidence of RA across the globe. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia. By 2040, an estimated 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis.

Autoinjectors Market

Home care settings to dominate the autoinjectors market during the forecast period

A majority of autoinjectors are used for self-administration of drugs and are rarely recommended for hospital use to avoid the risk of infection due to use on multiple patients. This is a major factor in driving the market growth. Other factors such as the growing prevalence of chronic diseases and technological advancements are also boosting this market segment.

North America to witness the highest market growth during the forecast period

The large share of the North American autoinjectors market can primarily be attributed to the rising prevalence of autoimmune and chronic diseases, increasing prevalence of anaphylaxis, and the increasing number of FDA approvals in the region.

Autoinjectors Market

Market Dynamics

Driver: Favorable reimbursements and government support

In the US, autoinjectors are covered on a co-payment basis by most insurance plans, including Medicare Part D. These co-payments and preferred statuses vary based on the plan. In addition, savings allied with a preferred brand are different. In Canada, the coverage for autoinjectors varies across provinces, with a majority of provinces providing full reimbursement for these devices. For instance, the Ontario Drug Benefit ODB program reimburses 100% of the cost of allergy shots and epinephrine autoinjectors in Canada.

The favorable reimbursement environment and government support encouraging the use of autoinjectors in these countries are expected to boost the demand for these devices in the coming years.

Restraint:  Preference for alternative drug delivery modes

Traditional injectables are invasive and painful modes of drug delivery owing to which patients and care providers are increasingly focusing on alternative routes of drug delivery, such as oral, topical, and nasal routes. Among the various routes of drug delivery, the oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable. Moreover, the introduction of needle-free drug delivery devices such as jet injectors also restricts the growth of the autoinjectors market. Antares Pharma, for example, offers jet injectors for the delivery of growth hormone in the US, Europe, Asia, and Japan.

Opportunity: Patent expiry of biologics to drive the demand for biosimilars

Biosimilars were introduced in 2006 by pharmaceutical companies such as Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), and JCR Pharmaceuticals Co., Ltd. (Japan). The demand for biosimilars has increased significantly, due to their lower costs. The impending patent expiry of many biologic molecules will also serve to drive the demand for biosimilars.
Even insurance companies and governments are favoring the use of biosimilars and generics. For instance, CVS Caremark, a major prescription insurer in the US, has replaced branded injectable drugs such as Copaxone by Teva and EpiPen by Mylan with their generic counterparts Glatiramer Acetate (Auto-injector) by Mylan and Adrenaclick (an auto-injector) by Amedra Pharmaceuticals. Since many injectables for the treatment of chronic diseases are biologics, the expiry of patents and growing support from governments and insurance providers provides an opportunity for growth.

Challenge: Development of autoinjectors for multiple drug viscosities

The biggest challenge faced by original equipment manufacturers (OEM) is developing single-design autoinjectors for multiple drugs and biologics with varying viscosities. Drugs with different viscosities require springs with different physical characteristics such as composition, length, and thickness to create a spring rate that provides enough power to push higher viscosity drugs and biologics through the syringe to the needle. Currently, most pharma OEMs lack the knowledge required to create autoinjectors that are capable of delivering multiple drugs and biologics with varying viscosities. However, players are working on overcoming this problem. MW Industries (US) is currently working on a solution in collaboration with OEM and NPD firms to design an autoinjector for multiple drug viscosities.

Scope of the Report

Report Metric

Details

Market size available for years

2016–2023

Base year considered

2017

Forecast period

2018–2023

Forecast units

USD million and billion

Segments covered

Therapy, Type, End-User, and Region

Geographies covered

North America, APAC, Europe, and Rest of the World

Companies covered

Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US) Merck (US), SHL Group (Taiwan), Ypsomed (Switzerland), AstraZeneca (UK), Becton Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), J&J (US), Haselmeier (Switzerland), Consort Medical (France), Antares Pharma (US)

The research report categorizes the autoinjectors market into the following segments and subsegments:

By Therapy

  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Diabetes
  • Anaphylaxis
  • Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia)

By Type

  • Disposable Autoinjectors
  • Reusable Autoinjectors

By End-User

  • Home Care Settings
  • Hospital & Clinics

By Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • APAC
    • Japan
    • China
    • India
    • Rest of APAC
  • Rest of the World

Key Market Players

SHL Group, Becton Dickinson and Company, Ypsomed, Owen Mumford, Haselmeier

Recent Developments

  • In 2018, Abbvie and Samsung Bioepis signed a licensing agreement to launch Humira biosimilar in Europe.
  • In 2018, Amgen collaborated with Simcere to co-develop and commercialize biosimilars in China.
  • In 2018, Haselmeier partnered with Common Sensing to develop self-monitoring injector platforms, which will help patients to record the time and amount of every dose.
  • In 2017, Ypsomed opened a new manufacturing facility in Solothurn (Switzerland). This new facility will focus on the production of injection systems.
  • In 2017, Johnson & Johnson received FDA approval of SIMPONI for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).

Critical questions the report answers:

  • Which are the most significant revenue-generating regions for the market?
  • What are the significant upcoming trends in the market?
  • How will the market drivers, restraints, and future opportunities affect the market dynamics?
  • Which end-user segment is expected to witness maximum growth opportunities during the forecast period?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 14)
    1.1 Objectives of Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Years Considered for the Study
           1.3.2 Markets Covered
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 17)
    2.1 Research Methodology Steps
    2.2 Secondary and Primary Research Methodology
           2.2.1 Secondary Research
           2.2.2 Primary Research
                    2.2.2.1 Key Data From Primary Sources
                    2.2.2.2 Key Industry Insights
    2.3 Market Size Estimation Methodology
    2.4 Market Data Validation and Triangulation
    2.5 Assumptions for the Study

3 Executive Summary (Page No. - 27)

4 Premium Insights (Page No. - 31)
    4.1 Market Overview
    4.2 Market, By Type, 2018 vs 2023
    4.3 Geographic Analysis: Market, By Therapy
    4.4 Market, By End User, 2018 vs 2023
    4.5 Geographic Snapshot: Market

5 Market Overview (Page No. - 35)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Growing Prevalence of Targeted Therapies
                    5.2.1.2 Rising Incidence of Anaphylaxis
                    5.2.1.3 Increasing Number of Regulatory Approvals
                    5.2.1.4 Availability of Generic Versions of Autoinjectors
                    5.2.1.5 Favorable Reimbursements and Government Support
                    5.2.1.6 Technological Advancements and Design Development
           5.2.2 Restraints
                    5.2.2.1 Preference for Alternative Drug Delivery Modes
                               5.2.2.1.1 Oral Diabetic Agents and Oral Insulin
                               5.2.2.1.2 Epinephrine Nasal Sprays
           5.2.3 Opportunities
                    5.2.3.1 Patent Expiry of Biologics to Drive the Demand for Biosimilars
           5.2.4 Challenges
                    5.2.4.1 Development of Autoinjectors for Multiple Drug Viscosities
                    5.2.4.2 Lack of Proper Training for Using Autoinjectors

6 Autoinjectors Market, By Therapy (Page No. - 42)
    6.1 Introduction
    6.2 Rheumatoid Arthritis
    6.3 Multiple Sclerosis
    6.4 Diabetes
    6.5 Anaphylaxis
    6.6 Other Therapies

7 Autoinjectors Market, By Type (Page No. - 50)
    7.1 Introduction
    7.2 Disposable Autoinjectors
    7.3 Reusable Autoinjectors

8 Autoinjectors Market, By End User (Page No. - 55)
    8.1 Introduction
    8.2 Home Care Settings
    8.3 Hospitals & Clinics

9 Autoinjectors Market, By Region (Page No. - 60)
    9.1 Introduction
    9.2 North America
           9.2.1 US
           9.2.2 Canada
    9.3 Europe
           9.3.1 Germany
           9.3.2 UK
           9.3.3 France
           9.3.4 Rest of Europe
    9.4 Asia Pacific
           9.4.1 Japan
           9.4.2 China
           9.4.3 India
           9.4.4 RoAPAC
    9.5 Rest of the World

10 Competitive Landscape (Page No. - 94)
     10.1 Overview
     10.2 Market Share Analysis
     10.3 Market Ranking of OEM Companies
     10.4 Market Share Analysis, By Therapeutic Area
             10.4.1 Rheumatoid Arthritis
             10.4.2 Multiple Sclerosis
             10.4.3 Diabetes
             10.4.4 Anaphylaxis
     10.5 Competitive Scenario
             10.5.1 Product Launches and Approvals
             10.5.2 Expansions
             10.5.3 Agreements, Collaborations, and Partnerships

11 Company Profiles (Page No. - 101)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     11.1 Abbvie
     11.2 Mylan
     11.3 ELI Lilly
     11.4 Ypsomed
     11.5 Amgen
     11.6 Becton, Dickinson and Company
     11.7 Owen Mumford
     11.8 Consort Medical
     11.9 Haselmeier
     11.10 Shl Group (Scandinavian Health Limited)
     11.11 Johnson & Johnson (J&J)
     11.12 Teva
     11.13 Antares Pharma

*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 125)
     12.1 Discussion Guide
     12.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     12.3 Available Customizations
     12.4 Related Reports
     12.5 Author Details


List of Tables (66 Tables)

Table 1 Recent Approvals of Autoinjector Devices Across the Globe
Table 2 Patent Expiry of Key Biologics
Table 3 Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 4 Autoinjectors Market for Rheumatoid Arthritis, By Country, 2016–2023 (USD Billion)
Table 5 Autoinjectors Market for Multiple Sclerosis, By Country, 2016–2023 (USD Billion)
Table 6 Autoinjectors Market for Diabetes, By Country, 2016–2023 (USD Million)
Table 7 Autoinjectors Market for Anaphylaxis, By Country, 2016–2023 (USD Million)
Table 8 Autoinjectors Market for Other Therapies, By Country, 2016–2023 (USD Million)
Table 9 Comparison of Disposable & Reusable Autoinjectors
Table 10 Market, By Type, 2016–2023 (USD Billion)
Table 11 Disposable Market, By Country, 2016–2023 (USD Billion)
Table 12 Reusable Market, By Country, 2016–2023 (USD Million)
Table 13 Market, By End User, 2016–2023 (USD Billion)
Table 14 Autoinjectors Market for Home Care Settings, By Country, 2016–2023 (USD Billion)
Table 15 Autoinjectors Market for Hospitals & Clinics, By Country, 2016–2023 (USD Million)
Table 16 Autoinjectors Market, By Region, 2016–2023 (USD Billion)
Table 17 North America: Market, By Country, 2016–2023 (USD Billion)
Table 18 North America: Market, By Therapy, 2016–2023 (USD Billion)
Table 19 North America: Market, By Type, 2016–2023 (USD Billion)
Table 20 North America: Market, By End User, 2016–2023 (USD Billion)
Table 21 Autoinjectors Approved By the Fda, 2015–2018
Table 22 US: Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 23 US: Market, By Type, 2016–2023 (USD Billion)
Table 24 US: Market, By End User, 2016–2023 (USD Billion)
Table 25 Canada: Market, By Therapy, 2016–2023 (USD Million)
Table 26 Canada: Market, By Type, 2016–2023 (USD Million)
Table 27 Canada: Market, By End User, 2016–2023 (USD Million)
Table 28 Product Approvals in Europe, 2015–2018
Table 29 Europe: Autoinjectors Market, By Country, 2016–2023 (USD Billion)
Table 30 Europe: Market, By Therapy, 2016–2023 (USD Billion)
Table 31 Europe: Market, By Type, 2016–2023 (USD Billion)
Table 32 Europe: Market, By End User, 2016–2023 (USD Billion)
Table 33 Germany: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 34 Germany: Market, By Type, 2016–2023 (USD Billion)
Table 35 Germany: Market, By End User, 2016–2023 (USD Billion)
Table 36 UK: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 37 UK: Market, By Type, 2016–2023 (USD Billion)
Table 38 UK: Market, By End User, 2016–2023 (USD Billion)
Table 39 France: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 40 France: Market, By Type, 2016–2023 (USD Billion)
Table 41 France: Market, By End User, 2016–2023 (USD Billion)
Table 42 RoE: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 43 RoE: Market, By Type, 2016–2023 (USD Million)
Table 44 RoE: Market, By End User, 2016–2023 (USD Million)
Table 45 Asia Pacific: Autoinjectors Market, By Country, 2016–2023 (USD Billion)
Table 46 Asia Pacific: Market, By Therapy, 2016–2023 (USD Billion)
Table 47 Asia Pacific: Market, By Type, 2016–2023 (USD Billion)
Table 48 Asia Pacific: Market, By End User, 2016–2023 (USD Billion)
Table 49 Japan: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 50 Japan: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 51 Japan: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 52 China: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 53 China: Market, By Type, 2016–2023 (USD Million)
Table 54 China: Market, By End User, 2016–2023 (USD Million)
Table 55 India: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 56 India: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 57 India: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 58 RoAPAC: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 59 RoAPAC: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 60 RoAPAC: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 61 RoW: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 62 RoW: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 63 RoW: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 64 Product Launches and Approvals
Table 65 Expansions
Table 66 Agreements, Collaborations, and Partnerships


List of Figures (36 Figures)

Figure 1 Autoinjectors Market: Research Methodology Steps
Figure 2 Break Down of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Research Design
Figure 6 Data Triangulation Methodology
Figure 7 Rheumatoid Arthritis Therapy Segment to Dominate the Autoinjectors Market in 2018
Figure 8 Disposable Autoinjectors to Account for the Largest Share of the Autoinjectors Market in 2018
Figure 9 Home Care Settings to Dominate the Autoinjectors Market During the Forecast Period
Figure 10 North America to Witness the Highest Market Growth During the Forecast Period
Figure 11 Growing Prevalence of Targeted Therapies and Increasing Number of Regulatory Approvals are Driving Market Growth
Figure 12 Disposable Autoinjectors to Dominate the Market in 2018
Figure 13 Rheumatoid Arthritis Therapy Segment to Command the Largest Share of the Autoinjectors Market in 2018
Figure 14 Home Care Settings to Account for the Largest Market Share in 2018
Figure 15 North America to Witness the Highest Growth Rate During the Forecast Period
Figure 16 Autoinjectors Market: Drivers, Restraints, Opportunities, & Challenges
Figure 17 Autoinjectors Market, By Therapy, 2018 vs 2023 (USD Billion)
Figure 18 Autoinjectors Market, By Type, 2018 vs 2023 (USD Billion)
Figure 19 Autoinjectors Market, By End User, 2018 vs 2023 (USD Billion)
Figure 20 North America to Command the Largest Market Share in 2018
Figure 21 North America: Autoinjectors Market Snapshot
Figure 22 Europe: Autoinjectors Market Snapshot
Figure 23 Asia Pacific: Autoinjectors Market Snapshot
Figure 24 RoW: Autoinjectors Market Snapshot
Figure 25 Market Ranking of OEM Companies
Figure 26 Strategies Adopted By Market Players (2014–2018)
Figure 27 Abbvie: Company Snapshot (2017)
Figure 28 Mylan: Company Snapshot (2017)
Figure 29 ELI Lilly: Company Snapshot (2017)
Figure 30 Ypsomed: Company Snapshot (2017)
Figure 31 Amgen: Company Snapshot (2017)
Figure 32 BD: Company Snapshot (2017)
Figure 33 Consort Medical: Company Snapshot (2017)
Figure 34 Johnson & Johnson: Company Snapshot (2017)
Figure 35 Teva: Company Snapshot (2017)
Figure 36 Antares Pharma: Company Snapshot (2017)


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
3 0 4 8 3  
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
MD 6494
Published ON
Aug, 2018
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Autoinjectors Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home